CCR Agonists

Cat.No.	Product Name	Information	Product Use Citations
S2003	Maraviroc (UK-427857)	Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.	Nat Commun, 2025, 16(1):4591 Adv Sci (Weinh), 2025, 12(8):e2411711 J Nanobiotechnology, 2025, 23(1):696
S8220	INCB3344	INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.	Biomedicines, 2025, 13(7)1763 MedComm (2020), 2024, 5(5):e535 Commun Biol, 2024, 7(1):488
S8501	Adaptavir (DAPTA)	Adaptavir (DAPTA, D-Ala-peptide T-amide, peptide T) is a water soluble potent, selective CCR5 antagonist which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.	Cell Death Dis, 2022, 13(5):478 Proc Natl Acad Sci U S A, 2021, 118(9)e2017282118 FEBS J, 2020, 287(11):2367-2385
S7604	BX471 (ZK-811752)	BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.	Nat Commun, 2025, 16(1):4581 Commun Biol, 2024, 7(1):1304
S3383	RS102895	RS 102895 is a small molecule antagonist of CCR2 with an IC50 of 360 nM.	Exp Mol Med, 2024, 56(2):408-421. Theranostics, 2022, 12(17):7351-7370
S0085	BMS-813160	BMS-813160 is a potent, well-absorbed dual CCR2 and CCR5 chemokine antagonist. This compound inhibits inflammatory processes, angiogenesis, tumour cell migration, tumour cell proliferation and invasion.	Commun Biol, 2024, 7(1):1304 Mater Today (Kidlington), 2023, 62:33-50
S0129	SB-297006	SB-297006 is an antagonist of C-C chemokine receptor 3 (CCR3) that suppresses antigen-induced accumulation of T(h)2 as well as eosinophils in the lungs. This compound suppressed CCL11-induced Th2 chemotaxis with IC50 of 2.5 μM.	JHEP Rep, 2023, 5(9):100805 Cell Death Dis, 2022, 13(5):478
S3494	Vicriviroc maleate	Vicriviroc maleate (SCH-417690 maleate, SCH-D maleate) is a potent, selective, orally bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells.	Breast Cancer Res, 2021, 23(1):11
S9738	RS504393	RS504393, an extremely selective CC chemokine receptor (CCR) 2 antagonist with IC50 of 98 nM, also targets multiple receptors for inhibition of CCR2b and CCR1 receptors when administrated in higher concentration.	Mol Psychiatry, 2024, 10.1038/s41380-024-02826-9
S6555	AZD2098	AZD2098 is a potent and bioavailable CCR4 receptor antagonist with pIC50 of 7.8.	Neurooncol Adv, 2022, 4(1):vdab194
S8361	PF-4136309	PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2.	Signal Transduct Target Ther, 2025, 10(1):81
E4715	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S7538	RS-102895 Hydrochloride	RS-102895 hydrochloride (HCl) is a potent antagonist of Chemokine (C-C motif) receptor 2 (CCR2) with IC50 of 360 nM, and shows no effect on CCR1. RS-102895 hydrochloride also inhibits human α1a and α1d receptors, rat brain cortex 5-HT1a receptor in cells with IC50s of 130 nM, 320 nM, 470 nM, respectively.
E0486	C-021	C-021 is a potent CCR4 antagonist with IC50 values of 0.14 μM and 39 nM for inhibition of chemotaxis in human and mouse respectively.
E0395	Vercirnon	Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9.
E5955^New	CCR6 antagonist 1	CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
S0438	TAK-779	TAK-779 (Takeda 779), a nonpeptide compound, is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.